(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ministry: New German petrol price regulation takes effect on April 1 - 2Improving as a Pioneer: Examples from My Vocation
- 3Vote In favor of Your Favored Kind Of Organic product
- 4Novo and Lilly cut prices of weight-loss drugs in China
- 5Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- Fundamental Home Machines: An Easy to understand Determination Guide
- Northern lights chances rise for Christmas as space weather remains unsettled
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Truly amazing Palaces: Which Is Your Number one?
- This cafe takes orders in sign language. It's cherished by the Deaf community
- Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
